Durezol®

Mechanism of Action

Difluprednate is a prodrug converted to difluoroprednisolone by corneal esterases. The difluoro substitution increases glucocorticoid receptor binding affinity and anti-inflammatory potency. The emulsion vehicle enhances corneal penetration.

Common Clinical Applications

• Postoperative inflammation and pain following ocular surgery
• Anterior uveitis
• Endogenous anterior uveitis

Typical Dosing Principles

For postoperative inflammation: one drop four times daily for 2 weeks, then twice daily for 1 week, then once daily for 1 week. For uveitis: one drop four times daily, tapering based on response.

Dosing information is provided for educational purposes. Always consult current prescribing information for specific dosing protocols.

Important Precautions

• Higher potency increases IOP risk compared to prednisolone acetate — vigilant monitoring required.
• Posterior subcapsular cataract risk with prolonged use.
• Contraindicated in viral, fungal, and mycobacterial infections.
• Fibrin formation in the anterior chamber has been reported with overuse.

Clinical Pearls

• Approximately twice the anti-inflammatory potency of prednisolone acetate 1% — meaningful for severe inflammation.
• Twice-daily dosing for postoperative inflammation may improve compliance vs. four-times-daily regimens.
• IOP monitoring is particularly important given the higher potency.
• The emulsion vehicle does not require shaking — a practical advantage over suspension formulations.

Commonly Associated Disease States

Select any disease state to explore its full entry in the Disease State Library.